Orencia® (abatacept) (DrugBank: Abatacept)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 95 | Autoimmune hepatitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04203875 (ClinicalTrials.gov) | March 9, 2020 | 12/12/2019 | Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis | Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis | Autoimmune Hepatitis | Drug: Orencia® (Abatacept) | Stuart Knechtle, M.D. | NULL | Recruiting | 18 Years | N/A | All | 5 | Phase 1 | United States |